SIKE1

Across TCGA pan-cancer cohorts, SIKE1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SIKE1 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SIKE1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SIKE1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, UCEC, and HNSC are the cancer types where SIKE1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.454	0.253	.006	20	view →
UCEC	DFS	Tertile	All	0.983	0.779	.001	18	view →
HNSC	DFS	Tertile	All	0.810	0.265	.020	13	view →
LUAD	OS	Median	II,III,IV	0.429	0.911	.008	4	view →
CCRCC	DFS	Median	All	0.600	0.927	.024	4	view →
LSCC	DFS	Quartile	All	1.000	0.379	.013	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SIKE1–PDAC (DFS)

Open the PDAC breakdown →